SCHEMBL29520847

SCHEMBL29520847

FC(n1ncc2ccccc21)C(F)(F)F

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RECQL P46063 1/20 0.39
CYP1A2 P05177 1/20 0.36
KMO O15229 1/20 0.35
ELANE P08246 1/20 0.34
DDB1 Q16531 1/20 0.33
CRBN Q96SW2 1/20 0.33
CYP11B1 P15538 1/20 0.33
CYP11B2 P19099 1/20 0.33
ADRA2A P08913 2/20 0.33
ADRA2B P18089 1/20 0.33
ADRA2C P18825 1/20 0.33
MEN1 O00255 2/20 0.31
RAB9A P51151 2/20 0.31
KMT2A Q03164 2/20 0.31
SLC22A12 Q96S37 1/20 0.31
KDM4E B2RXH2 1/20 0.31
ALDH1A1 P00352 1/20 0.31
LMNA P02545 1/20 0.31
TP53 P04637 1/20 0.31
GAA P10253 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29602247 0.81 RECQL (0.43) RECQLCYP1A2KMOELANEDDB1
SCHEMBL493365 0.81 RECQL (0.43) RECQLCYP1A2KMOELANEDDB1
SCHEMBL28947642 0.81 RECQL (0.38) RECQLCYP1A2KMOELANEDDB1
SCHEMBL878425 0.73 RECQL (0.43) RECQLCYP1A2KMOELANEDDB1
SCHEMBL29350890 0.73 RECQL (0.43) RECQLCYP1A2KMOELANEDDB1
SCHEMBL21276545 0.70 RECQL (0.41) RECQLCYP1A2KMOELANEDDB1
SCHEMBL29311539 0.70 RECQL (0.41) RECQLCYP1A2KMOELANEDDB1
SCHEMBL20622947 0.70 RECQL (0.41) RECQLCYP1A2KMOELANEDDB1
SCHEMBL17188069 0.70 P2RX7 (0.47) RECQLCYP1A2KMOELANEDDB1
SCHEMBL12915266 0.70 RECQL (0.41) RECQLCYP1A2KMOELANEDDB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11649255-B2 Indazoles as hematopoietic progenitor kinase 1 (HPK1) inhibitors and methods using same 1ST Biotherapeutics, Inc. (KR) 2023-05-16 US disclosed
US-20220098193-A1 INDAZOLES AS HEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) INHIBITORS AND METHODS USING SAME 1ST Biotherapeutics, Inc. 2022-03-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11649255-B2 Indazoles as hematopoietic progenitor kinase 1 (HPK1) inhibitors and methods using same IP6K1, HIPK1, IP6K3 RECQL 1162/4885CYP1A2 1840/4885KMO 1689/4885
US-20220098193-A1 INDAZOLES AS HEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) INHIBITORS AND METHODS USING SAME IP6K1, HIPK1, IP6K3 RECQL 1162/4885CYP1A2 1840/4885KMO 1689/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.